What is hit to lead stage in drug discovery?
The hit-to-lead (H2L) stage in drug discovery involves refining initial chemical hits with desired therapeutic effects by synthesizing, testing, and optimizing compounds through methods like structure-activity relationships, computational modeling, and high-throughput screening to identify and improve lead candidates with enhanced potency, specificity, and drug-like properties for further development.
Hit to lead (H2L) is one of the key stages of the early drug discovery process. Hits are chemical compounds with a desired therapeutic effect at a known target molecule. The lead is the product of the screening process, useful in advanced stages of drug discovery.
The goal of the H2L stage is to identify the most favored candidates for further progress at later stages of the drug discovery process. This goal is completed by identifying molecule candidates that interact with the drug objective. These candidates are known as leads and are optimized to improve properties for their function as effective drugs.
What happens in the hit-to-lead process?
As the continual process of improving the lead, H2L typically involves synthesizing and testing many compounds to determine the most promising leads.
During this stage, researchers work to refine the starting compounds using various screening test techniques. The tests aim to help optimize characteristics important for drug development, including potency and specificity. This optimization process may involve modifying chemical structures or altering their delivery systems.
Once a lead has been identified, further optimization will ensure the molecule is proper. Modifications are made to improve the chemical properties as required.
Approaches to hit to lead optimization
Approaches used for drug optimization in the H2L stage include:
- Structure-activity relationships (SAR): Used to understand the relationship between the structure and activity of a compound.
- Computational modeling: Computational models can help predict the properties of potential leads without requiring timely and expensive experiments in the laboratory.
- High-throughput screening: High-throughput screening relies on testing many compounds, going through most or all possible combinations for use. This is in contrast to approaches such as SARs, which aim to narrow the pool of potential compounds.
Related
Reasonable Expectations, Clean Data, Collaboration: The Three Keys to AI in Drug Discovery
The article explains that while AI and machine learning have long been used in drug discovery, recent hype and massive investments have led to unrealistic expectations, emphasizing that success depends on setting reasonable goals, ensuring clean and abundant data, and fostering collaboration, as most AI-driven drug candidates remain in early development stages and face complex biological and practical challenges.
FAQ center
The FAQ center explains that lab automation uses data science to create intelligent systems reducing human input, digital labs fully digitize operations for efficiency, future labs will heavily rely on robotics and integrated data management, lab compliance ensures safe and effective lab practices, data integrity ensures reliable data quality, scientific data management systems (SDMS) facilitate safe and accessible scientific data handling, and open data differs from FAIR data in accessibility and usability requirements.
Lead Pharma: Increasing Research Throughput with an ELN for Chemists and Biologists
Lead Pharma accelerates cancer and autoimmune disease drug discovery by integrating medicinal, structural, and computational chemistry with cell biology and omics technologies to develop first- and best-in-class small molecules, target protein production, and advanced assays and biomarkers.
Data Management, Collaboration, and Workflow Optimisation: The Three Keys to Small Molecule Discovery Success
The article emphasizes that despite biologics' prominence, small molecule drug discovery is experiencing a renaissance driven by advances in screening, target exploration, and AI, but overcoming challenges like rising costs, data management, fragmented workflows, and CRO reliance requires success in three key areas: next-generation data management, enhanced cross-disciplinary research collaboration, and workflow optimization.
Webinar: Three Key Considerations When Implementing AI in Drug Discovery
The webinar, led by Haydn Boehm, focuses on three key considerations—reasonable expectations, clean data, and collaboration—for successfully implementing AI in small molecule drug discovery amidst the current hype and ongoing preclinical development of AI-native candidates.
Integrating Animals, Assays, and Therapeutics to Simplify In Vivo Study Management
Dotmatics and RockStep have partnered to offer an integrated electronic platform that streamlines in vivo study management, registration, and assay data, enabling real-time monitoring and improved drug discovery efficiency, as demonstrated by a webinar comparing traditional methods with digitalized workflows where a digitally equipped company outperforms a traditional one in developing an IBD drug faster and more cost-effectively.